The Problem:

Current epinephrine auto-injectors, such as EpiPen, suffer from temperature sensitivity, bulkiness, and lack features to assist first responders. Epinephrine degrades quickly when exposed to changing temperatures, and many users find traditional auto-injectors too large to carry daily, increasing the risk of being unprepared in an anaphylactic emergency. Additionally, the absence of an injection timer can lead to uncertainties during emergency response.

The Solution:

Epi+ is a medical device startup focused on innovating epinephrine auto-injectors. Our mission is to enhance the reliability, portability, and effectiveness of emergency epinephrine delivery for individuals with severe allergies. Unlike existing solutions, Epi+ prioritizes temperature regulation, compactness, and the inclusion of an injection timer for first responders, addressing critical limitations in the market.

Why Now:

The global epinephrine market is valued at over $2 billion, With an anticipated CAGR of 11.6% during the forecast period 2024-2031 due to rising allergy diagnoses and regulatory pushes for accessibility. The primary EpiPen patent expires in 2025, opening a key opportunity for innovation. With Epi+, we’re not just improving an auto-injector—we’re setting a new standard in emergency allergy care and providing a long-overdue solution in epinephrine delivery.

Our Website:

https://www.epiplus.net/